Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2018 Aug;32(8):1768-1777.
doi: 10.1038/s41375-018-0210-1. Epub 2018 Jul 20.

Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia

Robert J Kreitman  1 , Claire Dearden  2 , Pier Luigi Zinzani  3 , Julio Delgado  4 , Lionel Karlin  5 , Tadeusz Robak  6 , Douglas E Gladstone  7 , Philipp le Coutre  8 , Sascha Dietrich  9 , Mirjana Gotic  10 , Loree Larratt  11 , Fritz Offner  12 , Gary Schiller  13 , Ronan Swords  14 , Larry Bacon  15 , Monica Bocchia  16 , Krimo Bouabdallah  17 , Dimitri A Breems  18 , Agostino Cortelezzi  19 , Shira Dinner  20 , Michael Doubek  21 , Bjorn Tore Gjertsen  22 , Marco Gobbi  23 , Andrzej Hellmann  24 , Stephane Lepretre  25 , Frederic Maloisel  26 , Farhad Ravandi  27 , Philippe Rousselot  28   29 , Mathias Rummel  30 , Tanya Siddiqi  31 , Tamar Tadmor  32 , Xavier Troussard  33 , Cecilia Arana Yi  34 , Giuseppe Saglio  35 , Gail J Roboz  36 , Kemal Balic  37 , Nathan Standifer  37 , Peng He  38 , Shannon Marshall  38 , Wyndham Wilson  1 , Ira Pastan  1 , Nai-Shun Yao  38 , Francis Giles  39
Affiliations
Multicenter Study

Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia

Robert J Kreitman et al. Leukemia. 2018 Aug.

Abstract

This is a pivotal, multicenter, open-label study of moxetumomab pasudotox, a recombinant CD22-targeting immunotoxin, in hairy cell leukemia (HCL), a rare B cell malignancy with high CD22 expression. The study enrolled patients with relapsed/refractory HCL who had ≥2 prior systemic therapies, including ≥1 purine nucleoside analog. Patients received moxetumomab pasudotox 40 µg/kg intravenously on days 1, 3, and 5 every 28 days for ≤6 cycles. Blinded independent central review determined disease response and minimal residual disease (MRD) status. Among 80 patients (79% males; median age, 60.0 years), durable complete response (CR) rate was 30%, CR rate was 41%, and objective response rate (CR and partial response) was 75%; 64 patients (80%) achieved hematologic remission. Among complete responders, 27 (85%) achieved MRD negativity by immunohistochemistry. The most frequent adverse events (AEs) were peripheral edema (39%), nausea (35%), fatigue (34%), and headache (33%). Treatment-related serious AEs of hemolytic uremic syndrome (7.5%) and capillary leak syndrome (5%) were reversible and generally manageable with supportive care and treatment discontinuation (6 patients; 7.5%). Moxetumomab pasudotox treatment achieved a high rate of independently assessed durable response and MRD eradication in heavily pretreated patients with HCL, with acceptable tolerability.

PubMed Disclaimer

Conflict of interest statement

This study was sponsored by MedImmune. RJK received a research grant from MedImmune and is co-inventor of moxetumomab pasudotox, with the NIH holding the patent. CD has received personal fees from Gilead, Infinity, Janssen/Pharacyclics, MedImmune, Roche, and Sanofi Aventis, and has received clinical trial support from MedImmune. PLZ has served as an advisor for Bristol-Myers Squibb, Celgene, Gilead, Janssen, Merck, Roche, Servier, and Takeda. JD served on a data monitoring board for MedImmune, has received research grants from Janssen and Roche, and has received personal fees from Abbvie, Gilead, Janssen, and Roche. LK, DEG, M Gotic, LL, FO, RS, GS, SD, LB, CAY, AH, KB, MB, MG, AC, MD, SD, SL, MR, PR, TT, GS, GJR, XT, and WW have no conflicts to report. TR has received research grants from AstraZeneca. PLC has served as a speaker for Bristol-Myers Squibb, Incyte, Novartis, and Pfizer. DAB has received personal fees from Amgen, Novartis, and Teva, and his institution has received reimbursement for clinical trials from Ablynx, Amgen, Astellas, Astex, Cyclacel, Genzyme, Janssen, MedImmune, Merus, Menarini, Novella Clinical, Pfizer, and Seattle Genetics. BTG has received personal fees from BerGenBio AS, Novartis AS, Pfizer, and Seattle Genetics, received non-financial support from Merck Sharpe & Dohme and Roche, and owns shares in Alden Cancer Therapeutics 2 AS and Kinn Therapeutics AS. FM has received research grants from Amgen and Sandoz, received travel accommodations from Octapharma and Roche, and served on advisory boards for Pfizer, Roche, and Sandoz. FR has received research grants from MedImmune. TS has served on speakers’ bureaus for Pharmacyclics and Seattle Genetics, and on a steering committee for Juno. KB, NS, PH, SM, and NSY are employees of MedImmune and may own stock/options in AstraZeneca. IP is co-inventor of moxetumomab pasudotox, with the NIH holding the patent. FG has received a research grant from MedImmune.

Figures

Fig. 1
Fig. 1
Evaluation of primary end point (blinded independent central review). a Hemoglobin (top), neutrophil counts (middle), and platelet counts (bottom) over time, as a function of best objective response. Median and interquartile range are shown at each displayed time point and the threshold for hematologic remission is indicated as a dotted line. b HCL involvement in bone marrow, assessed by hematoxylin and eosin stain, as a function of best objective response; median and interquartile range are shown (top), and as representative pretreatment and posttreatment images (×100) of a patient who obtained a minimal residual disease-negative complete response (bottom). Yellow arrows indicate hairy cells. c Spleen size by imaging, as a function of best objective response. Median and interquartile range are shown. Splenectomy patients (n = 5) not included. d Kaplan–Meier plot of duration of hematologic remission from complete response
Fig. 2
Fig. 2
Assessment of minimal residual disease by immunohistochemistry (blinded independent central review). a Representative immunohistochemistry images from pretreatment and posttreatment bone marrow biopsy specimens of the same patient shown in Fig. 1b: CD20 (left) and PAX5/TRAP (right). b Kaplan–Meier plot of duration of complete response, by minimal residual disease status
See this image and copyright information in PMC

References

    1. Grever MR, Blachly JS, Andritsos LA. Hairy cell leukemia: update on molecular profiling and therapeutic advances. Blood Rev. 2014;28:197–203. doi: 10.1016/j.blre.2014.06.003. - DOI - PubMed
    1. Rosenberg JD, Burian C, Waalen J, Saven A. Clinical characteristics and long-term outcome of young hairy cell leukemia patients treated with cladribine: a single-institution series. Blood. 2014;123:177–83. doi: 10.1182/blood-2013-06-508754. - DOI - PubMed
    1. Kreitman RJ. Immunoconjugates and new molecular targets in hairy cell leukemia. Hematol Am Soc Hematol Educ Program. 2012;2012:660–6. - PMC - PubMed
    1. Thompson PA, Ravandi F. How I manage patients with hairy cell leukaemia. Br J Haematol. 2017;177:543–56. doi: 10.1111/bjh.14524. - DOI - PubMed
    1. Else M, Dearden CE, Matutes E, Garcia-Talavera J, Rohatiner AZ, Johnson SA, et al. Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis. Br J Haematol. 2009;145:733–40. doi: 10.1111/j.1365-2141.2009.07668.x. - DOI - PubMed

Publication types

MeSH terms